ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES USE OF MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning entitled, The Potential and Pitfalls of Using Multi-Criteria Decision Analysis to Support Health Technology Assessment. The session took place at the Society’s 19th Annual European Congress in Vienna, Austria. The workshop was led by discussion leaders that included:
  • Janine A. van Til, PhD, Assistant Professor Preference Research, Health Technology and Services Research, University of Twente, Enschede, The Netherlands
  • Rob Baltussen, PhD, Associate Professor Health Economics, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
  • Michele Tringali, MD, Director, HTA Program, Lombardy Region Health Directorate, Milan, Italy
  • Susanne Schmitz, PhD, Postdoctoral Fellow, Department of Population Health/Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg
The workshop reviewed a number of practical examples to illustrate how health technology assessment (HTA) and reimbursement decisions can be supported with multi-criteria decision analysis (MCDA). The panelists discussed the apparent fit between MCDA and HTA decision making and reviewed the use of a deliberative approach to MCDA that involves stakeholder consultation. Case studies from the Netherlands, Thailand, and Indonesia were presented and results of a retrospective analysis demonstrated potentially important drivers of reimbursement decisions in Ireland and outlined the challenges of using such information to inform an actual MCDA framework. A number of knowledge products on MCDA have been developed by ISPOR’s Multi-Criteria Decision Analysis in Health Care Decision Making Task Force, including the following Task Force Reports published in Value in Health: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×